Clinical Trial Update: Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update on biochemical response to interferon-gamma in subjects with a CGD gene mutation; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease

Drugs mentioned

• Interferon-gamma (interferon gamma)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: IFN-Gamma Therapy, CGD Gene Mutation | Phase 4 | Status: TERMINATED | Results posted: 2017-09-20